LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aktien・NeoGenomics Inc

NeoGenomics Inc

Geschlossen

9.23 1.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.19

Max

9.25

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.2M -17M
Verkäufe	-3.5M 187M
EPS	0.01
Gewinnspanne	-9.164
Angestellte	2,500
EBITDA	-5.8M -567K

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+61.76% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	28. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-31M 1.1B
Vorheriger Eröffnungskurs	7.69
Vorheriger Schlusskurs	9.23

NeoGenomics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

NeoGenomics Inc Prognose

Kursziel

By TipRanks

61.76% Vorteil

12-Monats-Prognose

Durchschnitt 14.93 USD 61.76%

Hoch 25 USD

Tief 11 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für NeoGenomics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für NeoGenomics Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.